Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

Cyclin-dependent kinases (CDKs) are potential cancer therapeutic targets because of their critical role in promoting cell growth. Dinaciclib is a novel CDK inhibitor currently under clinical evaluation for the treatment of advanced malignancies. In this study, we demonstrated the anti-tumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajput, Sandeep, Khera, Nimmish, Guo, Zhanfang, Hoog, Jeremy, Li, Shunqiang, Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302958/
https://www.ncbi.nlm.nih.gov/pubmed/27486754
http://dx.doi.org/10.18632/oncotarget.10870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302958/
https://www.ncbi.nlm.nih.gov/pubmed/27486754
http://dx.doi.org/10.18632/oncotarget.10870

Ejemplares similares